{‘She lacks little experience’: the US scientific establishment prepares for Høeg's appointment at the Food and Drug Administration.

While the United States proceeds with sweeping revisions to its vaccination guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the global health crisis and has concentrated on alleged fatalities following Covid vaccination in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities had intended to unveil radical changes to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of alignment with many the international standard with no evidence for benefit. This reveal has been pushed back until the coming year.

In place of Vinay Prasad, Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to head the office this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some childhood vaccine recommendations in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the domain of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Expertise

Høeg has no obvious experience in medication creation, regulation or administrative roles, which has been customary for past directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who led CBER have had.”

CDER has an vast portfolio at the agency, Woodcock pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be looked after,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management element to the position, which oversees over 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” Woodcock concluded.

Official Statement and Contentious Policies

Regarding inquiries about Høeg’s qualifications and whether this assignment indicates greater collaboration among agency officials on immunizations, a press secretary said that the “inquiries rely on flawed presumptions”.

“This background matches the duties of her position,” the official stated, pointing to the time Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a disputed one-day medication authorization process that apparently troubled her preceding directors. “By what process are these medications being selected for this expedited pathway? Who is making the choices?” Dr. Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent oversight of all drugs, with the exception of shots.”

Established Track Record on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, critics observe. She authored a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation after Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the incoming government featured revising regulations for recently developed shots and ending “optional” immunizations, she remarked post-election on a online show. At the FDA, Høeg has reportedly suggested preventing teenage boys from getting COVID-19 vaccines.

“She is an all-around true believer who commences with her conclusions and reverse-engineers to retrofit the science in a highly misleading, untruthful way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|